|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
News
Altravax, Inc. Awarded $1.2M To Advance Dengue Vaccine And Hepatitis Therapeutic
January 8, 2013
Altravax，公司获得120万美元，推进
登革热疫苗及肝炎治疗性疫苗
FARGO, N.D. & SUNNYVALE, CALIF.--(BUSINESS WIRE)--
Altravax, Inc. announced today that it has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH’s National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax’s two lead commercial programs.
“These awards further validate the strength of our vaccine technology,” said Michael Chambers, interim CEO of Altravax. Chambers noted Altravax has received over $4.5 million in non-dilutive funding in recent months, which will be instrumental in bringing these critical products closer to market.
2013年1月8日
法戈，ND桑尼维尔，加利福尼亚州 - （BUSINESS WIRE） -
Altravax，公司今天宣布，它已经获得了两科高级科技小企业创新研究资助，由美国国立卫生研究院的国立过敏和传染病的疫苗研究，以避免感染登革热病毒，这些病毒治疗慢性乙型肝炎的每Altravax的两个领先的商业计划是一个全球性问题的焦点。
“这些奖项进一步验证了我们的疫苗技术实力，说：”临时CEO迈克尔·钱伯斯的Altravax。钱伯斯指出，Altravax在最近几个月已经收到了超过450万美元的非摊薄资金，这将有助于使这些关键的产品更贴近市场。
|
|
发表于 2013-1-10 19:17
